Janssen in Zug is the Swiss sales and marketing subsidiary of the research-based, global leader in the pharmaceutical industry. The company develops pharmaceutical preparations for pain relief, gynecology, neurology, psychiatry and virology. Janssen has developed over 80 drugs, five of which are included in the WHO list of the most important medications.
Johnson & Johnson and Janssen are deeply engrained in Switzerland. Janssen is the combination of Janssen –founded by Dr. Paul Janssen in Belgium in 1953, and acquired by Johnson & Johnson in 1961 and Cilag, acquired in 1959. Cilag was founded by Dr. Bernhard Joos in Switzerland in 1936. In 1994 Janssen and Cilag merged and since 2010 are operating under the Janssen brand name.
Contact
Janssen-Cilag AG
Gubelstrasse 34
CH-6300 Zug
tel +41 58 231 34 46
Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients,…
Working to stay ahead in the highly competitive medical device field, Boston Scientific’s Philippe Hügli launched a Customer Insight Initiative in Switzerland which has served as a pilot for the…
Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma…
Soho Flordis International (SFI) has the ambition to be a global leader in premium natural healthcare solutions, and is leveraging extensive M&A activities to reach this goal. Group head of…
Italian-speaking Swiss canton Ticino outperforms most regions within Europe, yet still lags behind the high-flying cantons of Northern Switzerland. Stefano Rizzi, director of the canton’s economic division, discusses its economic…
With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of…
Niche generics manufacturer Rivopharm was nearly bankrupt when acquired by current president and CEO Piero Poli in 2005; he explains the changes and strategy he put in place to drive…
www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond.…
As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH,…
Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause of MS, as well as the reasons for choosing…
Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their…
The Services Delivery Director for Life Sciences of NNIT Switzerland talks big data and highlights how this trend needs to be approached in order to create value for companies in…
Daniel Schmutz, CEO of Switzerland’s leading insurance company, Helsana, sketches out the Swiss health insurance landscape, how his company maintains its market leader position, and working with both national and…
See our Cookie Privacy Policy Here
